CD274 and neoplasm: In the Checkmate‐026 and Checkmate‐227 studies, patients whose tumours expressed high levels of PD‐L1 and had high tissue TMB status derived the greatest benefit from treatment with the anti‐PD‐1 antibody nivolumab, measured by ORR and PFS [21, 22, 23].